CAGRILINTIDE

Originally developed by Novo Nordisk, this synthetic amylin analog has gained attention primarily as part of combination therapy research with GLP-1 receptor agonists. While amylin itself was discovered decades ago as a hormone co-secreted with insulin, cagrilintide represents a modified version designed for extended activity in metabolic research. Most current investigation focuses on its potential to enhance weight loss when paired with established diabetes medications.

This peptide targets amylin receptors found throughout the brain and digestive system, mimicking a hormone that healthy pancreases release alongside insulin after meals. When activated, these receptors send signals that make people feel full sooner, slow down how quickly food moves through the stomach, and dial back the liver's glucose production between meals. Think of it as hitting multiple metabolic brakes simultaneously—reducing both how much people want to eat and how aggressively their bodies process glucose.